症状性良性前列腺增生与初次全髋关节置换术后假体周围关节感染及假体周围关节感染相关翻修风险无关
基于PearlDiver数据库的回顾性队列研究,纳入113,366例男性初次全髋关节置换术患者,其中症状性良性前列腺增生患者按1:4匹配。结果显示两组在30天、90天和2年假体周围关节感染风险及5年无假体周围关节感染相关翻修生存率上无显著差异,但症状性良性前列腺增生组术后30天和90天导尿、尿路感染和脓毒症风险更高。
要点
- 症状性良性前列腺增生患者初次全髋关节置换术后30天、90天和2年假体周围关节感染风险与无此病患者无显著差异。
- 症状性良性前列腺增生患者术后30天和90天导尿、尿路感染及脓毒症风险显著高于无此病患者。
- 两组5年无假体周围关节感染相关翻修生存率无显著差异(98.3% vs 98.1%;p=0.10)。
核心结论
- 症状性良性前列腺增生在初次全髋关节置换术男性受者中常见,骨科医生应意识到该亚组术后泌尿系统并发症和脓毒症的额外风险,可能需要额外的术后护理。
- 作者建议可考虑围手术期措施,如术前使用简短问卷评估泌尿症状、泌尿科会诊或转诊以及更密切的随访,以改善接受全髋关节置换术的症状性良性前列腺增生患者的护理。
- 由于目前评估症状性良性前列腺增生的工具有限且缺乏敏感性和特异性,未来研究可能开发经过验证的工具,用于术前快速评估症状性良性前列腺增生患者的风险。
研究设计与样本
- 回顾性队列研究,使用PearlDiver数据库,纳入2010年1月至2021年4月期间接受初次全髋关节置换术的患者。
- 初始识别1,056,119例患者,应用纳入标准(男性、最低年龄18岁、髋关节骨关节炎诊断)和排除标准(无症状性良性前列腺增生史或任何其他关节置换史)后剩余16%(172,866例)。
- 进一步排除未达到最低2年随访的6%(59,500例)患者,最终11%(113,366例)纳入分析。
- 症状性良性前列腺增生患者按年龄和合并症(包括酒精滥用、贫血、心血管疾病、慢性肺病、糖尿病、抑郁、肥胖、外周血管疾病、肾衰竭和类风湿关节炎)以1:4比例与无此病患者匹配,匹配后两组年龄和合并症均衡。
- 采用逻辑回归分析术后30天、90天和2年并发症的比值比,采用Kaplan-Meier法估计5年无假体周围关节感染相关翻修生存率并用对数秩检验比较。
主要发现
- 在65岁及以上男性初次全髋关节置换术受者中,24%(11,319/47,426)有症状性良性前列腺增生病史。
- 术后30天假体周围关节感染发生率:症状性良性前列腺增生组0.5%(62/11,819)vs 无此病组0.5%(227/47,103),OR 1.09(95%CI 0.82至1.43)。
- 术后90天假体周围关节感染发生率:症状性良性前列腺增生组0.8%(97/11,819)vs 无此病组0.8%(360/47,103),OR 1.07(95%CI 0.85至1.34)。
- 术后2年假体周围关节感染发生率:症状性良性前列腺增生组1.3%(150/11,819)vs 无此病组1.2%(570/47,103),OR 1.05(95%CI 0.87至1.25)。
- 症状性良性前列腺增生组相比无此病组,术后30天和90天导尿的OR分别为5.00(95%CI 3.64至6.88)和5.36(95%CI 4.04至7.13),尿路感染的OR分别为2.18(95%CI 1.88至2.54)和2.55(95%CI 2.26至2.87),脓毒症的OR分别为1.55(95%CI 1.11至2.13)和1.43(95%CI 1.10至1.83)。
临床怎么用
- 作者认为,骨科医生应意识到接受全髋关节置换术的症状性良性前列腺增生患者术后泌尿系统并发症和脓毒症的额外风险,可能需要额外的术后护理。
- 作者建议,可考虑围手术期措施如术前使用简短问卷评估泌尿症状、泌尿科会诊或转诊以及更密切的随访,以改善该类患者的护理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Symptomatic benign prostatic hyperplasia (sBPH) is a potential risk factor for periprosthetic joint infection (PJI), a leading cause of implant failure and revision THA. However, the available evidence is mixed on whether this is the case. QUESTIONS/PURPOSES: (1) What is the prevalence of sBPH in male recipients of primary THA by age group? (2) Do patients with sBPH compared with those without sBPH have higher 30-day, 90-day, and 2-year odds of PJI and higher 30-day and 90-day odds of urinary catheterization, urinary tract infection (UTI), and sepsis after primary THA? (3) Do patients with sBPH compared with those without sBPH have lower survivorship free from PJI-related revision at 5 years after THA? METHODS: The PearlDiver database was used as it provided the largest sample of patients across all payer types to perform longitudinal research. Between January 2010 and April 2021, 1,056,119 patients who underwent primary THA were identified. After applying the inclusion criteria (that is, male sex, minimum age of 18, and diagnosis of hip osteoarthritis) and exclusion criteria (that is, history of asymptomatic BPH or any other joint arthroplasty), 16% (172,866) of patients remained. A further 6% (59,500) of patients were excluded as they did not meet the minimum study follow-up of 2 years, leaving 11% (113,366) for analysis. Of those, patients with sBPH were matched to those without in a 1:4 ratio by age and comorbidities, including alcohol abuse, anemia, cardiovascular disorders, chronic pulmonary disease, diabetes mellitus, depression, obesity, peripheral vascular disorders, renal failure, and rheumatoid arthritis. Age and comorbidities of the two groups postmatch were balanced. Logistic regression was performed to analyze the odds for 30-day, 90-day, and 2-year postoperative complications. Survivorship free from PJI-related revision at 5 years after THA was estimated using the Kaplan-Meier method and compared with the log-rank test. RESULTS: Among male recipients of primary THA ages 65 or older, 24% (11,319 of 47,426) had a medical history of sBPH. We found no difference in the odds of PJI at 30 days, 90 days, and 2 years after primary THA between the two groups. PJI occurred in 0.5% (62 of 11,819), 0.8% (97 of 11,819), and 1.3% (150 of 11,819) of patients with sBPH versus in 0.5% (227 of 47,103), 0.8% (360 of 47,103), and 1.2% (570 of 47,103) of those without sBPH within 30 days (OR 1.09 [95% CI 0.82 to 1.43]), 90 days (OR 1.07 [95% CI 0.85 to 1.34]), and 2 years (OR 1.05 [95% CI 0.87 to 1.25]) after THA, respectively. Patients with sBPH compared with those without had higher odds of 30-day and 90-day urinary catheterization (OR 5.00 [95% CI 3.64 to 6.88] and OR 5.36 [95% CI 4.04 to 7.13], respectively), 30-day and 90-day UTI (OR 2.18 [95% CI 1.88 to 2.54] and OR 2.55 [95% CI 2.26 to 2.87], respectively), and 30-day and 90-day sepsis (OR 1.55 [95% CI 1.11 to 2.13] and OR 1.43 [95% CI 1.10 to 1.83], respectively). We found no difference in survival free from PJI-related revision at 5 years after THA between patients with and without sBPH (98.3% [95% CI 98.1% to 98.6%] versus 98.1% [95% CI 98.1% to 98.2%]; p = 0.10). CONCLUSION: sBPH is common among THA recipients, and surgeons should be aware of the added risk of postoperative urinary complications and sepsis in this subset that could lead to additional postoperative care requirements. Surgeons may consider perioperative measures such as preoperative use of short-form questionnaires to assess urinary symptoms, urology clearance or referral, and closer follow-up to improve care of sBPH patients undergoing THA. As currently available tools for assessing sBPH are limited and lack sensitivity as well as specificity, future studies may develop validated tools that can be used to quickly assess risk in sBPH patients before surgery. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Jeong S, Lee JW, Boucher HR, et al. Symptomatic Benign Prostatic Hyperplasia Is Not Associated With a Higher Risk of Periprosthetic Joint Infections and Periprosthetic Joint Infection-related Revisions After Primary THA. Clin Orthop Relat Res. 2023. PMID: 37458699. doi:10.1097/CORR.0000000000002766
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。